Hyderabad-based Aurobindo Pharmaceuticals is gearing up to develop and manufacture multiple Covid-19 vaccine candidates. It has taken help from the Department of Biotechnology (DBT) for its own vaccine candidate and has also tied up with the Council of Scientific and Industrial Research (CSIR) for the multiple vaccine candidates the latter is developing.
Biotechnology Industry Research Assistance Council (BIRAC), a not-for-profit enterprise set up by the DBT, has facilitated the establishment of the r-VSV vaccine manufacturing platform for Aurobindo. The company is developing a Sars-Cov-2 vaccine through its wholly-owned US-based subsidiary Auro Vaccines based on its proprietry replication-competent attenuated (weakened) recombinant